Head-to-head · WeighScore
Claya vs Corsica Health
The verdict
Corsica Health takes it — 66.3/100 to 62.8/100.
Corsica Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Corsica Health is a telehealth platform offering both compounded GLP-1s and brand-name FDA-approved injections through a structured assessment, provider review, and medication flow.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Claya | Corsica Health |
|---|---|---|
| WeighScore | 62.8/100 | 66.3/100 |
| Grade | C | C |
| Scorecard rank | #267 | #193 |
| Semaglutide | $299/mo (compounded) | $249/mo (compounded) |
| Tirzepatide | $299/mo (compounded) | $349/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #267 · C
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
Where it loses points
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Graded #193 · C
Strengths
- Public pricing shown for both compounded and brand-name options — a real transparency advantage
- $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
- LegitScript Certified
- Clear 3-step intake: Assessment, Provider Review, Receive Medication
- $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced
Where it loses points
- Legal entity name and state of incorporation not disclosed on the site
- Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
- Per-state availability not listed publicly
- First-month promotional pricing not disclosed
- Lab-work inclusion not clearly disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.